6-cyano-2,3-dihydroxy-7-nitroquinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-cyano-2,3-dihydroxy-7-nitroquinoxaline
• 英文别名: CNQX；2,3-dihydroxy-7-nitroquinoxaline-6-carbonitrile
• 化学式: C₉H₄N₄O₄
• 分子量: 232.155
• InChiKey: RPXVIAFEQBNEAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6 -氰基喹喔啉-2,3二酮 生成 6-cyano-2,3-dihydroxy-7-nitroquinoxaline
  参考文献：
  名称：

  6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical

  摘要：

  具有以下公式的杂环二羟基喹喔啉化合物 ##STR1## 其中R.sup.1是卤素，CN，CF.sub.3，乙炔或N.sub.3，R.sup.2是SO.sub.2 C.sub.1-3 -烷基，CF.sub.3，NO.sub.2，乙炔或CN。本发明还涉及制备该化合物的方法，其制药组合物以及它们的用途。该化合物可用于治疗由兴奋性神经递质引起的症状，特别是谷氨酸受体，尤其是作为神经类药物。

  公开号：

  US04812458A1

文献信息

• NOVEL PYRROLIDINE DERIVATIVES
  申请人：UNIVERSITE CLAUDE BERNARD LYON I

  公开号：US20150175537A1

  公开（公告）日：2015-06-25

  The present invention relates to novel pyrrolidine derivatives of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and X are as defined in claim 1 , optionally in a zwitterionic form, in the form of a pure optical isomer, or in the form of a mixture of optical isomers in any proportions, or in a form enriched with an optical isomer, as well as their pharmaceutically acceptable salts, solvates or hydrates, and pharmaceutical compositions containing such compounds. These compounds are notably useful for treating, in particular in human beings, epilepsy, ischemia, neurodegenerative diseases such as Parkinson's disease or Huntington's chorea, multiple sclerosis, Devic's disease, Alzheimer's disease, psychiatric diseases such as schizophrenia, depression, addiction, allodynia and hyperalgia.

  本发明涉及公式(I)的新型吡咯烷衍生物：其中R1、R2、R3、R4、R5和X如权利要求书中定义的，可选地为带电离形式，以纯的光学异构体形式、或以任何比例的光学异构体混合物形式、或以富含光学异构体的形式存在，以及它们的药学上可接受的盐、溶剂合物或水合物，以及含有这些化合物的药物组合物。这些化合物特别适用于治疗，特别是在人类中，癫痫、缺血、帕金森病或亨廷顿舞蹈病等神经退行性疾病、多发性硬化症、德维克病、阿尔茨海默病、精神疾病如精神分裂症、抑郁症、成瘾、痛觉过敏和疼痛过敏。
• 1H-QUINAZOLINE-2,4-DIONES
  申请人：NOVARTIS AG

  公开号：US20130296332A1

  公开（公告）日：2013-11-07

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范所定义，它们的制备，它们作为药物的用途，以及含有它们的药物组合物。此外，还公开了制造公式(I)化合物的中间体和包含公式(I)化合物的组合物。
• Method of screening binding of a compound to a receptor
  申请人：——

  公开号：US20030215959A1

  公开（公告）日：2003-11-20

  Disclosed is a method of measuring affinity of a test compound for a receptor protein. The method includes the steps of providing a receptor-ligand complex comprising a receptor and a quinoxaline derivative ligand bound thereto; then contacting the receptor-ligand complex with a test compound, thereby yielding a receptor-test compound complex and an amount of free quinoxaline derivative; and then measuring the amount of the free quinoxaline derivative generated as a result of the previous step. In this fashion, the affinity of the test compound for the receptor can be determined.

  本发明公开了一种测量试验化合物与受体蛋白亲和力的方法。该方法包括以下步骤：提供一个包括受体和一个喹喔啉衍生物配体结合在一起的受体-配体复合物；然后将受体-配体复合物与试验化合物接触，从而产生受体-试验化合物复合物和一定量的游离喹喔啉衍生物；然后测量由于前一步骤而产生的游离喹喔啉衍生物的数量。通过这种方法，可以确定试验化合物与受体的亲和力。
• 1H-Quinazoline-2,4-Diones
  申请人：Allgeier Hans

  公开号：US20080153836A1

  公开（公告）日：2008-06-26

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式（I）的1H-喹唑啉-2,4-二酮，其中R1和R2如规范中所定义，它们的制备，它们作为药物的用途以及含有它们的药物组合物。此外，还揭示了制造公式（I）化合物的中间体和包含公式（I）化合物的组合物。
• Quinazoline Derivatives
  申请人：Allgeier Hans

  公开号：US20070208018A1

  公开（公告）日：2007-09-06

  The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.

  本发明涉及式(I)的1H-喹唑啉-2,4-二酮衍生物，其中取代基的定义如规范中所述，它们的制备方法，它们作为药物的用途，以及含有它们的药物组合物。